Dimerix (ASX:DXB) Lands $481M Everest Medicines Deal to Advance Kidney Disease Therapy Across Asia

Key Highlights

• Dimerix (ASX:DXB) signs licensing deal with Everest Medicines worth up to AU$481.2 million
 • Agreement includes AU$14.1 million upfront payment and tiered royalties of 10% to 15%
 • DMX-200 targets FSGS, a rare kidney disease with no approved targeted therapies in key Asian markets
 • Partnership expands Dimerix’s global licensing network to five regional deals worth up to AU$1.9 billion
 • DXB shares surge 18.18% following the announcement

Dimerix (ASX:DXB) has strengthened its global ambitions for kidney disease treatment DMX-200, signing a major licensing agreement with China-focused biopharmaceutical company Everest Medicines that could be worth up to AU$481.2 million.

The deal gives Everest exclusive rights to develop and commercialise DMX-200 across Greater China, South Korea and selected Southeast Asian countries, opening access to a region where hundreds of thousands of patients are believed to be living with focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disease.

For Dimerix, the agreement represents more than another licensing transaction. It adds a significant commercial partner in one of the world’s largest healthcare markets while providing fresh capital to support the company’s pivotal Phase 3 clinical program.

Under the terms of the agreement, Dimerix will receive an upfront payment of US$10 million, equivalent to approximately AU$14.1 million, within 45 business days. The company is also eligible for up to US$30 million in development and regulatory milestones, up to US$300 million in commercial milestones, and tiered royalties ranging from 10% to 15% on future net sales.

The market welcomed the news.

Dimerix shares climbed 18.18% to $0.195 in morning trade on Tuesday, with almost 9.8 million shares changing hands. The rally pushed the company’s market capitalisation to approximately $120 million and marked one of the strongest performances on the ASX healthcare board.

Source: MarketIndex 

The agreement arrives at a pivotal stage for DMX-200.

The drug candidate is currently being evaluated in the global ACTION3 Phase 3 trial for FSGS, a disease that causes scarring of the kidneys and can rapidly progress to kidney failure. The study has fully recruited 333 patients across 21 countries, including China, Hong Kong, Taiwan, Thailand and Malaysia.

While FSGS remains relatively unknown outside specialist medical circles, its impact can be devastating. Patients often face declining kidney function, dialysis or transplantation, and even transplanted kidneys can see the disease return in up to 60% of cases.

Importantly, there are currently no approved targeted therapies for FSGS in many Asian markets, leaving physicians reliant on broad immunosuppressive treatments and blood pressure medications.

That unmet need helps explain Everest’s interest.

The company has built a strong presence in renal diseases across Asia and sees DMX-200 as a potential addition to its growing kidney health portfolio.

The partnership also highlights how Dimerix has pursued a capital-efficient commercialisation strategy.

Rather than attempting to build costly global sales operations itself, the Melbourne-based biotechnology company has steadily licensed regional rights to established pharmaceutical partners. Including Everest, Dimerix has now secured five exclusive licensing agreements covering major international markets.

Collectively, those partnerships carry a potential value of approximately AU$1.9 billion, in addition to future royalty streams. Before the Everest deal, Dimerix had already received more than AU$65 million in upfront and milestone payments from its partners.

The timing is particularly significant because recent clinical updates have strengthened confidence in the Phase 3 program.

In April, an independent blinded review confirmed the ACTION3 study maintained greater than 90% statistical power to achieve its primary endpoint. Earlier this month, the Independent Data Monitoring Committee completed its eighth safety review without identifying any safety concerns.

Those developments have helped reduce some of the risks typically associated with late-stage biotechnology programs.

Dimerix Chief Executive Officer Dr Nina Webster said the agreement would significantly expand access to the therapy.

“We are delighted to establish this partnership with Everest Medicines, a company with strong rare renal disease expertise and a proven track record in commercialising in Greater China, South Korea and certain Southeast Asian countries. Importantly, this collaboration significantly expands the potential reach of DMX-200 into a large and underserved patient population.”

“Everest is well positioned to maximise the opportunity in the licensed regions, while allowing Dimerix to retain focus on progressing our global registrational program, delivering value for shareholders and providing real hope for patients with FSGS across the globe in need of treatment options.”

Everest Medicines Chairman Yifang Wu echoed the opportunity.

“This collaboration with Dimerix marks an important step in advancing our strategic focus in kidney disease and further strengthening our innovative renal portfolio. Patients with FSGS in China have long faced significant unmet medical needs due to the lack of targeted treatment options.”

For Dimerix, the latest agreement is another piece in a broader global strategy. The science remains the critical factor, with Phase 3 results still ahead. Yet by securing regional partners and building a substantial milestone pipeline, the company has positioned itself to pursue one of biotechnology’s most challenging goals: bringing a new treatment to patients while limiting shareholder dilution along the way.